TGTXHealthcare · BiotechnologyThe 8 Wall Street analysts covering TG Therapeutics, Inc. hold a median 12-month price target of $75 — +39.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 12 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores TG Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (10): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TGTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +39.2% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $78 |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | $65 → $72 |
| 27 July 2026 | B. Riley Securities | Maintains | Buy | $55 → $86 |
| 27 July 2026 | B. Riley Securities | Maintains | Buy | — |
| 13 July 2026 | HC Wainwright & Co. | Maintains | Buy | $70 → $77 |
| 13 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 July 2026 | B of A Securities | Maintains | Underperform | $17 → $20 |
| 7 July 2026 | B of A Securities | Maintains | Underperform | — |
| 6 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $70 |
| 6 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Feb 2026 | JP Morgan | Maintains | Overweight | — |
| 15 Jan 2026 | Goldman Sachs | Maintains | Neutral | — |
| 3 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 6 Oct 2025 | HC Wainwright & Co. | Assumes | Buy | $60 |
| 17 Sept 2025 | B. Riley Securities | Maintains | Buy | — |
| 4 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TGTX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, TG Therapeutics, Inc. returned +66.0% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 38% of US stocks
Cheaper than 14% of US stocks
Cheaper than 7% of US stocks
Cheaper than 4% of US stocks
Higher than 90% of US stocks
Higher than 6% of US stocks
Higher than 93% of US stocks
Higher than 62% of US stocks
Higher than 97% of US stocks
Higher than 96% of US stocks
Higher than 86% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
TG Therapeutics, Inc. has a market value of $8.2B and an enterprise value of $7.8B.
Revenue in the twelve months to 30 June 2026: $799.5M. The latest quarter grew 70.3% year on year.
Net income over the same four quarters: $441.5M, a 55.2% net margin.
Diluted earnings per share, trailing twelve months: $2.74.
Free cash flow in the twelve months to 30 June 2026: $17.4M.
TG Therapeutics, Inc. spent $178.2M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 19.7×; forward P/E: 18.2× — the forward figure prices analyst consensus estimates, not reported earnings.
TG Therapeutics, Inc. employs 399 people — $2.0M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own TG Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
TG Therapeutics announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. A fireside chat is scheduled for Monday, September 14, 2026, at 12:00pm ET.
Why it matters — A TGTX watcher would care because the presentation provides management an opportunity to update investors on the company at a major investment conference.
TG Therapeutics announced it will participate in the Cantor Global Healthcare Conference. The company said it would present at the event, according to the announcement.
Why it matters — Investors tracking TGTX may be interested in its participation in a major healthcare conference as a chance for company exposure and visibility.
TG Therapeutics reported earnings approximately 30 days ago, and its stock has risen 15.1% since then. The report examines whether the stock can continue its upward momentum following the earnings announcement.
Why it matters — TGTX watchers would care because the report assesses the stock's recent post-earnings performance and its potential for continued gains.
TG Therapeutics outlined upcoming catalysts for Q4 2026 and H1 2027, including preliminary Phase 1 azer-cel data in progressive MS in the second half of 2026 and topline Phase 3 data for Briumvi SC by year-end 2026 or early 2027. The company also raised its Briumvi U.S. net product revenue guidance from $885-$900 million to $890-$905 million.
Why it matters — TGTX watchers would care because the company has disclosed a timeline of major clinical data readouts and raised its Briumvi revenue outlook, signalling the potential for meaningful developments ahead.
Shares of TG Therapeutics rose this week after buyout rumors surfaced, with the company seen as a takeover target given Briumvi's growth and the de-risking of its recent subcutaneous formulation. The piece highlights strong standalone prospects regardless of merger-and-acquisition outcomes.
Why it matters — A TGTX watcher would care because buyout speculation, alongside Briumvi's growth and development milestones, could influence how the stock is valued in the near term.
The 8 Wall Street analysts covering TG Therapeutics, Inc. have a median 12-month price target of $75, with estimates ranging from $21 to $86. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering TG Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks TG Therapeutics, Inc. 68 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, TG Therapeutics, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +39.2% from the last close, and Ticker Nerd's factor model ranks TG Therapeutics, Inc. 68 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering TG Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TGTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $86 over the next 12 months.
TG Therapeutics, Inc. returned +66.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
TG Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for B-cell mediated diseases.
The most recent item we track (GlobeNewsWire, 10 Sept 2026): "TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference". TG Therapeutics announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. A fireside chat is scheduled for Monday, September 14, 2026, at 12:00pm ET.
TG Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for B-cell mediated diseases. The company’s lead product, BRIUMVI, is an anti-CD20 monoclonal antibody used for adults with relapsing forms of multiple sclerosis, including relapsing-remitting disease, clinically isolated syndrome, and active secondary progressive disease. TG Therapeutics also advances a broader pipeline of therapies, including subcutaneous and intravenous formulations of ublituximab, along with investigational programs such as Azer-cel. Its portfolio is centered on immune-related and hematologic conditions, reflecting a business model built around specialty medicines that target B-cell activity. TG Therapeutics serves patients and healthcare providers in the United States and internationally through its marketed products and development-stage candidates.
CEO Mr. Michael S. Weiss Esq., J.D. · 399 employees · United States · https://www.tgtherapeutics.com
